126 related articles for article (PubMed ID: 1839773)
1. [A comparison of the suppressor and cytotoxic activities of the blood mononuclear cells during the adoptive immunotherapy of cancer patients using lymphokine-activated killers with a low dose of recombinant interleukin-2].
Abronina IF; Kupriianova TA; Bolvachova AV; Bykovskaia SN; Dronova OM; Buachidze LI
Biull Eksp Biol Med; 1991 Nov; 112(11):519-21. PubMed ID: 1839773
[TBL] [Abstract][Full Text] [Related]
2. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
4. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
[TBL] [Abstract][Full Text] [Related]
5. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
Cancer Res; 1991 Mar; 51(5):1494-8. PubMed ID: 1997188
[TBL] [Abstract][Full Text] [Related]
6. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
[TBL] [Abstract][Full Text] [Related]
8. Autologous activated lymphocyte therapy in a community hospital.
Horváth J; Szabó-Szabari M; Sinkovics JG
Acta Microbiol Immunol Hung; 1994; 41(2):205-14. PubMed ID: 7804724
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
[TBL] [Abstract][Full Text] [Related]
10. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
12. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
14. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
15. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
16. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
17. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
